Heidelberg Pharma AG provided earnings guidance for the year 2022. The Executive Management Board currently expects the Heidelberg Pharma Group to generate between EUR 7.5 million and EUR 9.5 million in revenue and other income in the 2022 fiscal year. These will primarily comprise the sales revenue generated by Heidelberg Pharma Research GmbH and, to a lesser extent, potential milestone payments to Heidelberg Pharma AG.

Sales revenue is expected to increase due to the licensing agreement with Huadong. Loss before interest and taxes (LBIT) in the 2022 fiscal year are expected to be between EUR 32.5 million and EUR 36.5 million. With preliminary inclusion of the licensing agreement with Huadong, Heidelberg Pharma expects to post a significantly improved operating result.